Bavarian Nordic’s mpox vaccine to be trialled in pregnant women and infants
Bavarian Nordic’s mpox vaccine, Jynneos (MVA-BN), is set to be trialled in pregnant and breastfeeding women and infants. The Phase…
All articles by Abigail Beaney
Abigail Beaney
Abigail Beaney is a healthcare reporter for the Clinical Trials Arena. Coming from a journalistic background Abigail holds a BA (Hons) in Journalism from the University of Central Lancashire. Based in Manchester, Abigail has previously worked in local news and has interests in research into the treatment and prevention of cancer, heart disease and dementia.
-
-
Trump triumphs but impact on healthcare industry remains unclear
Donald Trump has been elected 47th president of the US after the 5 November election having won more than the…
-
Viking stock fluctuates amid manufacturing concerns with obesity pill
Shares in Viking Therapeutics jumped after the company shared positive data from an early-stage trial of its obesity pill but…
-
Endeveco Bio spin-off to launch obesity trial
Endevica Bio has launched a new spin-off company, Abisati, to accelerate its obesity candidate into clinical trials. The candidate, 710GO,…
-
ARIA-E risk of Lilly’s Kisunla in Alzheimer’s reduced with modified dosing
A modified dosing regimen with Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has shown a reduction in amyloid-related imaging abnormalities with…
-
J&J and Lilly both unveil IL-23 inhibitor efficacy in Crohn’s disease
Johnson & Johnson (J&J) and Eli Lilly have both revealed the efficacy of their interleukin-23 (IL-23) inhibitors to treat Crohn’s…
-
US Elections: how healthcare could look under a Harris or Trump administration
With less than three weeks before Americans head to the polls, the election race is heating up. It is still…
-
BIOSECURE Act: Companies turn to US manufacturers
The BIOSECURE Act’s impact is likely to benefit US-based manufacturing facilities as companies try to avoid falling foul of potential…
-
Cassava Sciences: Phase III trials storm ahead amid controversy
Cassava Sciences is moving forward with Phase III trials after paying $40m to settle an SEC case alleging misleading data…
-
Scholar Rock stocks skyrocket after SMA drug scores at Phase III
Scholar Rock’s stock has soared off the back of positive Phase III results from its spinal muscular atrophy (SMA) candidate.…